Journal of Surgery Concepts & Practice >

2024 , Vol. 29 >Issue 05: 414 - 425

DOI: https://doi.org/10.16139/j.1007-9610.2024.05.09

Original article

Expression and clinical significance of disulfidptosis-related LncRNA in gastric cancer

  • CHU Yudan ,
  • SUN Haidong ,
  • CUI Ran ,
  • ZHENG Hong
Expand
  • Department of Oncology, Shanghai Minhang Cancer Hospital, Shanghai 200240, China

Received date: 2024-08-25

  Online published: 2025-01-23

Fold

Abstract

Objective To construct prognostic model of disulfidptosis-related LncRNA (DRLncs) and explore the mechanism of LncRNA-small nucleolar RNA host genes（SNHG4） in promoting the progression of gastric cancer. Methods The multi-omics features of disulfidptosis genes in gastric cancer were first analyzed based on The Cancer Genome Atlas(TCGA) database. DRLncs were further screened, and disulfidptosis related gene recurrence score (DRG-RS) model was constructed to predict the overall survival(OS) and correlation with the clinical characteristics of gastric cancer patients. Differential gene analysis, functional enrichment and the correlation between chemotherapy efficacy in high- and low-risk groups were analyzed. Cell-counting kit-8 (CCK-8) assay and migration assay confirmed that LncRNA-SNHG4 promoted the malignant phenotype of gastric cancer cells. Western Blotting assay was used to detect the signaling pathway regulated by LncRNA-SNHG4. Results DRG-RS model including 8 DRLncs was successfully constructed, showing good performance in predicting OS of the patients with gastric cancer. DRG-RS model was significantly correlated with tumor-related signaling pathways, clinical characteristics and drug sensitivity of gastric cancer patients. LncRNA-SNHG4 expression was significantly increased in gastric cancer. LncRNA-SNHG4 promoted the proliferation and migration of gastric cancer cells. LncRNA-SNHG4 promoted the activation of Wnt signaling pathway in gastric cancer cells. Conclusions The DRG-RS model constructed in our study can stratify the prognosis of gastric cancer, and is closely related to malignant characteristics and chemotherapy efficacy of gastric cancer patients. The expression of LncRNA-SNHG4 significantly increased in gastric cancer tissues, and LncRNA-SNHG4 promoted the malignant phenotype of gastric cancer cells through the Wnt signaling pathway, suggesting that LncRNA-SNHG4 may play an important role in the progression of gastric cancer.

Key words： Gastric Cancer; Disulfidptosis; Disulfidptosis-related long non-coding RNA(LncRNA); LncRNA-small nucleolar RNA host gene (SNHG4); Wnt signaling pathway

Cite this article

CHU Yudan , SUN Haidong , CUI Ran , ZHENG Hong . Expression and clinical significance of disulfidptosis-related LncRNA in gastric cancer[J]. Journal of Surgery Concepts & Practice, 2024 , 29(05) : 414 -425 . DOI: 10.16139/j.1007-9610.2024.05.09

References

[1] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics,2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[2] GUAN W L, HE Y, XU R H. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1):57.
[3] WEI L, SUN J, ZHANG N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance[J]. Mol Cancer, 2020, 19(1):62.
[4] LE J, PAN G, ZHANG C, et al. Targeting ferroptosis in gastric cancer: strategies and opportunities[J]. Immunol Rev, 2024, 321(1):228-245.
[5] NEWTON K, STRASSER A, KAYAGAKI N, et al. Cell death[J]. Cell, 2024, 187(2):235-256.
[6] HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1):31-46.
[7] CARNEIRO B A, EL-DEIRY W S. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7):395-417.
[8] PISTRITTO G, TRISCIUOGLIO D, CECI C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging (Albany NY), 2016, 8(4):603-619.
[9] ZHANG C, LIU X, JIN S, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance[J]. Mol Cancer, 2022, 21(1):47.
[10] GAO W, WANG X, ZHOU Y, et al. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy[J]. Signal Transduct Target Ther, 2022, 7(1):196.
[11] FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487):eaaw5473.
[12] MAO C, WANG M, ZHUANG L, et al. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond[J]. Protein Cell, 2024, 15(9):642-660.
[13] ZHENG P, ZHOU C, DING Y, et al. Disulfidptosis: a new target for metabolic cancer therapy[J]. J Exp Clin Cancer Res, 2023, 42(1):103.
[14] XIAO F, LI H L, YANG B, et al. Disulfidptosis: a new type of cell death[J]. Apoptosis, 2024, 29(9-10):1309-1329.
[15] BRIDGES M C, DAULAGALA A C, KOURTIDIS A. LNCcation: lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045.
[16] WU Y, WEN X, XIA Y, et al. LncRNAs and regulated cell death in tumor cells[J]. Front Oncol, 2023,13:1170336.
[17] WANG R, YU X, YE H, et al. LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation[J]. J Biol Chem, 2024, 300(9):107680.
[18] LIU S, ZHENG Y, LI S, et al. Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses[J]. J Cancer Res Clin Oncol, 2023, 149(18):16851-16867.
[19] XU K, ZHANG Y, YAN Z, et al. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis[J]. Front Immunol, 2023,14:1205250.
[20] CHENG J, MA H, YAN M, et al. THAP9-AS1/miR-133b/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(4):401.
[21] JIA W, ZHANG J, MA F, et al. Long noncoding RNA THAP9-AS1 is induced by Helicobacter pylori and promotes cell growth and migration of gastric cancer[J]. Onco Targets Ther, 2019,12:6653-6663.
[22] DONG Q, QIU H, PIAO C, et al. LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network[J]. J Exp Clin Cancer Res, 2023, 42(1):209.
Options
Outlines

/

〈 〉